Zortress

Active Ingredient(s): Everolimus
FDA Approved: * April 20, 2010
Pharm Company: * NOVARTIS
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Zortress Overview

Everolimus (INN) (/vrolms/) (earlier code name RAD001) is the 40-O-(2-hydroxyethyl) derivative of sirolimus and works similarly to sirolimus as an inhibitor of mammalian target of rapamycin (mTOR). It is currently used as an immunosuppressant to prevent rejection of organ transplants and in the treatment of renal cell cancer and other tumours. Much research has also been conducted on everolimus and other mTOR inhibitors as targeted therapy for use in a number of cancers. It is marketed by No...

Read more Zortress Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Everolimus

Recent Zortress Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Everolimus
  • Suspension: 2mg, 3mg, 5mg
  • Tablet: 0.25mg, 0.5mg, 0.75mg, 10mg, 2.5mg, 5mg, 7.5mg
  • Tablet, For Suspension: 2mg, 3mg, 5mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Zortress: (4 results)

Sorted by National Drug Code
  • 0078-0414 Zortress 0.5 mg Oral Tablet by Novartis Pharmaceuticals Corporation
  • 0078-0415 Zortress 0.75 mg Oral Tablet by Novartis Pharmaceuticals Corporation
  • 0078-0417 Zortress 0.25 mg Oral Tablet by Novartis Pharmaceuticals Corporation
  • 0078-0422 Zortress 1 mg Oral Tablet by Novartis Pharmaceuticals Corporation

Other drugs which contain Everolimus or a similar ingredient: (4 results)






Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 16 December 2018.

We are committed to your privacy.

Copyright © 2005-2018 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA